compani
investor day guid bullish
updat sale guid our/con trulic
provid detail financi guidanc revenu guidanc revenu
our/con forecast management didnt specifi disconnect
vs street forecast believ trulic insulin franchis like driver
base underli trend thu rais forecast
respect period out-year rais ep given
higher opex partial off-set anticip buyback pipelin updat
comprehens detail highlight none needle-mov
reiter neutral po balanc risk/reward limit catalyst
present titrat data combo type diabet
detail data expect via upcom scientif disclosur management highli bullish
combo expect posit first-lin inject like
cannib trulic disclos titrat schedul includ everi
week step-up dose level interv lead achiev target
dose strength management comment titrat algorithm expect gener
toler compar current downplay efficaci trade-off
management ask numer question pfe/lli partner anti-ngf program
tanezumab chronic pain sever larg studi read
overal management feedback reinforc uncertainti previous flag
mechan caus rpoa side effect unknown data need
character clinic implic rpoa type joint space narrow vs sever
type total destruct joint management unclear caus imbal tjr
recent data first tanezumab acr mainli rpoa type
comp origin program limit type wasnt track serial imag
pipelin new indic
noteworthi could advanc popul previous treat
checkpoint inhibitor obes nash studi
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
acr american colleg
timestamp decemb estcr eli lilli compani
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
compani decemb
biopharmaceut compani
diversifi therapeut focu product
focus treat diseas condit
diabet cancer immunolog central nervou
system disord deep pipelin drug
therapeut focu mirror commerci
portfolio found
incorpor indiana top sell
product includ humalog sale
ciali alimta forteo
one highest ep growth name among
us major pharma new product launch
cost cut measur expect drive
neutral believ stock beat
street estim achiev multipl expans
given competit payer headwind
compani diabet categori
risk new brand launch disappoint consensu
verzenio taltz set tough target
unchang po base blend averag dcf
multipl ep dcf assum wacc vs prior reflect
compani decemb
compani
price object po base blend averag discount
cash flow dcf multipl appli ep dcf assum
wacc termin growth price-to-earnings multipl base regress analysi
histor us major pharma peer forward month price-to-earnings multipl three-
upsid risk po better-than-anticip margin expans on-going
cost-cut program verzenio show meaning clinic differenti
result signific uptak
downsid risk po slower growth trulic rapid biosimilar eros
humalog franchis slower growth new product launch
jason gerberri herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us major specialti pharmaceut coverag cluster
compani
compani decemb
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
compani decemb
